Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and spotlighting new targets like HER2 and Claudin 18.2.
Ronan J. Kelly, MD, MBA
Ronan Kelly, MD, MBA, specializes in medical oncology at Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas.
Articles by Ronan J. Kelly, MD, MBA
In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of nivolumab plus ipilimumab and look back on last year's ODAC meeting on its use in PD-L1–negative gastrointestinal cancers.
Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.